Industry News
Molecular pathway revealed for cancer progression of myeloid derived suppressor cells
Oct 02, 2014
InSilico Medicine and partners provide a clear, illustrative map that allows scientists to understand MDSC conditions, and furthermore the means to infiltrate themScientists from InSilico... Read More
Children's national researchers uncover therapeutic target linked to sepsis
Oct 02, 2014
Yang Liu, PhD, Director and Bosworth Chair of the Cancer Biology Center for Cancer and Immunology Research at Children's National Health System, and his colleagues Pan Zheng, MD, McKnew Professor... Read More
Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
Oct 02, 2014
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1. Read More
Colon tumor formation affected by genetic modifier
Oct 02, 2014
Unexpected results from an ongoing experiment in the lab of Kristi Neufeld, co-leader of the Cancer Biology Program at the University of Kansas Cancer Center, led to a potentially important discovery... Read More
Boosting the power of brain tumor treatments with transplant drug
Oct 02, 2014
Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts. Read More
Trastuzumab should remain as standard of care for HER2-positive breast cancer
Oct 02, 2014
Analysis of more than 8,000 women who participated in the world's largest study of two treatments for HER2-positive breast cancer reinforces other findings from the clinical trial showing that... Read More
Breast cancer: are men the forgotten victims?
Oct 01, 2014
In the US, 2,360 men will be diagnosed with breast cancer this year. But still, many people believe that it only affects women. We investigate the reasons why. Read More
Genetic test would help 'cut bowel cancer spread'
Oct 01, 2014
Screening families of patients with bowel cancer for a genetic condition would cut their risk of developing bowel, womb, and ovarian cancers, new research has found. Read More
Study: tumor BRACAnalysis CDx identifies 44 percent more candidates for PARP therapy
Oct 01, 2014
Myriad Genetics, Inc. has announced that its Tumor BRACAnalysis CDx™ companion diagnostic test significantly improved the detection of cancer-causing BRCA1/2 mutations by 44 percent in women... Read More
Survival results from phase III BREAK-3 study of Tafinlar® (dabrafenib) in patients with BRAF V600E-mutant metastatic melanoma
Oct 01, 2014
GSK has announced updated results for Tafinlar® (dabrafenib) from a planned analysis of the phase III BREAK-3 study in 250 patients with BRAF V600E mutant metastatic melanoma. Read More
Previous Page Next Page